Your browser doesn't support javascript.
Clinical research in ovarian cancer: consensus recommendations from the Gynecologic Cancer InterGroup.
Vergote, Ignace; Gonzalez-Martin, Antonio; Lorusso, Domenica; Gourley, Charlie; Mirza, Mansoor Raza; Kurtz, Jean-Emmanuel; Okamoto, Aikou; Moore, Kathleen; Kridelka, Frédéric; McNeish, Iain; Reuss, Alexander; Votan, Bénédicte; du Bois, Andreas; Mahner, Sven; Ray-Coquard, Isabelle; Kohn, Elise C; Berek, Jonathan S; Tan, David S P; Colombo, Nicoletta; Zang, Rongyu; Concin, Nicole; O'Donnell, Dearbhaile; Rauh-Hain, Alejandro; Herrington, C Simon; Marth, Christian; Poveda, Andres; Fujiwara, Keiichi; Stuart, Gavin C E; Oza, Amit M; Bookman, Michael A.
  • Vergote I; Belgium and Luxembourg Gynaecological Oncology Group (BGOG), Leuven, Belgium; University Hospitals Leuven, Leuven, Belgium. Electronic address: ignace.vergote@uzleuven.be.
  • Gonzalez-Martin A; Grupo Español de Cáncer de Ovario (GEICO), Madrid, Spain; Clinica Universidad de Navarra, Madrid, Spain; Program for Solid Tumors at Madrid, and Center for Applied Medical Research (CIMA), Universidad de Navarra, Pamplona, Spain.
  • Lorusso D; Multicenter Italian Trials in Ovarian Cancer and Gynecologic Malignancies (MITO), Naples, Italy; Fondazione Policlinico Gemelli IRCCS, Rome, Italy.
  • Gourley C; Scottish Gynaecological Cancer Trials Group (SGCTG), Cancer Research UK, Edinburgh, UK; Institute of Genetics and Cancer, University of Edinburgh, Edinburgh, UK.
  • Mirza MR; Nordic Society of Gynecologic Oncology Clinical Trial Unit (NSGO-CTU), Copenhagen, Denmark; Rigshospitalet, Copenhagen, Denmark.
  • Kurtz JE; Groupe d'Investigateurs National des Etudes des Cancers Ovariens et du Sein (GINECO), Paris, France; Strasbourg Cancer Institute, Strasbourg, France.
  • Okamoto A; Japanese Gynecologic Oncology Group (JGOG), Tokyo, Japan; The Jikei University School of Medicine, Tokyo, Japan.
  • Moore K; Gynecologic Oncology Group-Foundation (GOG-F), Philadelphia, PA, USA; OU Health Stephenson Cancer Center, Oklahoma City, OH, USA.
  • Kridelka F; Belgium and Luxembourg Gynaecological Oncology Group (BGOG), Leuven, Belgium; Centre Hospitalier Universitaire de Liège, Liège, Belgium.
  • McNeish I; National Cancer Research Institute (NCRI), London, UK; Department of Surgery and Cancer, Imperial College London, London, UK.
  • Reuss A; Arbeitsgemeinschaft Gynäkologische Onkologie (AGO) Study Group, Munich, Germany; Coordinating Center for Clinical Trials, Philipps University, Marburg, Germany.
  • Votan B; Association de Recherche Cancers Gynécologiques (ARCAGY)-GINECO, Paris, France.
  • du Bois A; Arbeitsgemeinschaft Gynäkologische Onkologie (AGO) Study Group, Munich, Germany; Kliniken Essen Mitte (KEM), Essen, Germany.
  • Mahner S; Arbeitsgemeinschaft Gynäkologische Onkologie (AGO) Study Group, Munich, Germany; University Hospital, Ludwig Maximilians University, Munich, Germany.
  • Ray-Coquard I; Groupe d'Investigateurs National des Etudes des Cancers Ovariens et du Sein (GINECO), Paris, France; Centre Leon Berard and University Claude Bernard Lyon I, Lyon, France.
  • Kohn EC; National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
  • Berek JS; Women's Cancer Research Network-Cooperative Gynecologic Oncology Investigators (WCRN-COGI), Fresno, CA; Stanford Cancer Institute, Stanford, CA, USA.
  • Tan DSP; Asia Pacific Gynecologic Oncology Trials Group (APGOT), Seoul, South Korea; Gynecologic Cancer Group Singapore (GCGS), Singapore; Cancer Science Institute, National University of Singapore, Singapore.
  • Colombo N; Mario Negri Gynecologic Oncology (MaNGO), Milan, Italy; European Institute of Oncology, Milan, Italy; University of Milano-Bicocca, Milan, Italy.
  • Zang R; Shanghai Gynecologic Oncology Group (SGOG), Shanghai, China; Zhongshan Hospital, Fudan University, Shanghai, China.
  • Concin N; AGO -Austria, Innsbruck, Austria; Kliniken Essen Mitte (KEM), Essen, Germany; Medical University of Innsbruck, Innsbruck, Austria.
  • O'Donnell D; Cancer Trials Ireland (CTI), Dublin, Ireland; St James's Hospital, Dublin, Ireland.
  • Rauh-Hain A; Global Gynecologic Oncology Consortium (G-GOC), Houston, TX, USA; MD Anderson Cancer Center, The University of Texas, Houston, TX, USA.
  • Herrington CS; Scottish Gynaecological Cancer Trials Group (SGCTG), Cancer Research UK, Edinburgh, UK; Institute of Genetics and Cancer, University of Edinburgh, Edinburgh, UK.
  • Marth C; AGO -Austria, Innsbruck, Austria; Medical University of Innsbruck, Innsbruck, Austria.
  • Poveda A; Grupo Español de Cáncer de Ovario (GEICO), Madrid, Spain; Hospital Quironsalud, Valencia, Spain.
  • Fujiwara K; Gynecologic Cancer Clinical Trials and Investigation Consortium (GOTIC), North Kanto, Japan; Saitama Medical University International Medical Center, Saitama, Japan.
  • Stuart GCE; Canadian Cancer Trials Group (CCTG), Kingston, ON, Canada; University of British Columbia, Vancouver, BC, Canada.
  • Oza AM; Princess Margaret Hospital Consortium (PMHC), Princess Margaret Cancer Centre, University of Toronto, Toronto, ON, Canada.
  • Bookman MA; Gynecologic Oncology Group-Foundation (GOG-F), Philadelphia, PA, USA; San Francisco Medical Center, San Francisco, CA, USA.
Lancet Oncol ; 23(8): e374-e384, 2022 08.
Article in English | MEDLINE | ID: covidwho-1960116
ABSTRACT
The Gynecologic Cancer InterGroup (GCIG) sixth Ovarian Cancer Conference on Clinical Research was held virtually in October, 2021, following published consensus guidelines. The goal of the consensus meeting was to achieve harmonisation on the design elements of upcoming trials in ovarian cancer, to select important questions for future study, and to identify unmet needs. All 33 GCIG member groups participated in the development, refinement, and adoption of 20 statements within four topic groups on clinical research in ovarian cancer including first line treatment, recurrent disease, disease subgroups, and future trials. Unanimous consensus was obtained for 14 of 20 statements, with greater than 90% concordance in the remaining six statements. The high acceptance rate following active deliberation among the GCIG groups confirmed that a consensus process could be applied in a virtual setting. Together with detailed categorisation of unmet needs, these consensus statements will promote the harmonisation of international clinical research in ovarian cancer.
Subject(s)
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Ovarian Neoplasms Type of study: Experimental Studies / Prognostic study / Randomized controlled trials Limits: Female / Humans Language: English Journal: Lancet Oncol Journal subject: Neoplasms Year: 2022 Document Type: Article

Similar

MEDLINE
LILACS
LIS
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Ovarian Neoplasms Type of study: Experimental Studies / Prognostic study / Randomized controlled trials Limits: Female / Humans Language: English Journal: Lancet Oncol Journal subject: Neoplasms Year: 2022 Document Type: Article